recap solid quarter driven organ recoveri
report solid result revenu well
street/jpm ep repres smaller beat vs
street/jpm due lower gross margin expenses/bonus tie
euroimmun acquisit look closer top-lin beat driven
organ acceler diagnost organ da
organ contribut euroimmun fx tailwind
end market perspect growth led environment low-teen
pharma follow food hsd academ slightli
declin look ahead compani issu guidanc fy organ
revenu target organ diagnost da
euroimmun ad ep target vs consensu
compani also guid revenu msd organ
translat ep rang vs consensu overal
acknowledg solid result recoveri core busi back
msd growth remain posit euroimmun deal see
initi take fy guidanc seem modest euroimmun
commerci ramp margin expans requir time effort materi
mind stock trade ev/ebitda believ much
organ growth recoveri deal posit alreadi price
continu see upsid area core tool
greater exposur attract inflect end market
greater margin upsid reiter neutral rate
increas dec pt
strong revenu beat organ growth recoveri acquisit fx
tailwind slight ep beat due lower gross oper margin
revenu well consensus/jpm driven
organ acceler diagnost organ da
organ contribut euroimmun fx tailwind
end market perspect growth led strength environment
low-teen pharma follow food hsd academ
china dd america lsd move gross margin
jpme due higher mix lower margin dx
revenu opm saw bp neg impact deal-rel
incent compens result ep vs street/jpm
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
guidanc call organ revenu growth ep along
quarterli result compani issu guidanc fy organ revenu
target organ diagnost da
euroimmun ad gross margin expect expand bp
partial off-set bp increas sg bp increas
 result expect opm expans bp translat
ep target vs consensu compani also guid
revenu msd organ translat ep rang vs
consensu lower mani expect manag
attribut season low euroimmun interest expens relat
acquisit long-term discuss healthcar confer earlier
month see takeaway compani expect hsd organ growth
driven hsd-dd growth dx includ euroimmun msd
growth da note repres acceler growth
maintain neutral overal acknowledg solid result
recoveri core busi back msd growth remain posit
euroimmun deal see initi take fy guidanc seem
modest euroimmun commerci ramp margin expans still
requir time effort materi mind stock trade
ev/ebitda believ organ growth recoveri deal posit
larg price continu see upsid area
core tool greater exposur attract inflect end market
greater margin upsid factor mind
reiter neutral rate increas dec pt
guidanc
guidanc
okay remov
invest thesi valuat risk
overal acknowledg recoveri core busi back msd growth
remain posit euroimmun deal see initi take
guidanc seem modest euroimmun commerci ramp margin
expans still requir time effort materi mind
stock trade ev/ebitda believ organ growth recoveri deal
posit larg price remain neutral
dcf-deriv decemb price target assum wacc
termin growth
risk rate price
upsid risk includ stronger expect growth new product launch
greater margin expans current anticip although seem harder
envis higher invest continu growth
screen signific driver expect
china slowdown uncertainti around capit deploy return
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
perkinelm summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
compani discuss report price report market close januari
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
